Articles related to TYPE 1 DIABETES

The study’s findings underscore the importance of addressing the high cost of insulin. Despite new products and discounts entering the market, one in four patients still report cost as a barrier to accessing their necessary insulin.

Explore how the newly FDA-cleared iLet Bionic Pancreas, integrating the iLet ACE Pump and the iLet Dosing Decision Software, could reshape the landscape of type 1 diabetes management through its adaptive and autonomous insulin dosing capabilities.

The Diabetes Plate Method streamlines meal planning for diabetes management. Utilizing a 9-inch plate, it divides meal components into nonstarchy vegetables, lean proteins, and carbohydrates. An efficient tool for physicians to guide patient dietary habits effectively.

Explore four decades of research illustrating the biphasic growth patterns in fetuses of diabetic and obese women, an essential yet overlooked factor in preventing childhood obesity. The comprehensive findings may redefine your approach to perinatal care and shape healthier futures for your patients.

Investigating how an insulin bolus affects the management of diabetic ketoacidosis reveals startling new information. In the diabetes field, experts widely use insulin as a core treatment for diabetic ketoacidosis (DKA). However, the debate over the best dosage and method of administration, specifically concerning the use of an initial insulin bolus, continues. This study evaluates the safety and effectiveness of this insulin bolus in DKA treatment. Employing a retrospective chart review, researchers examined patient outcomes for DKA treatment with and without an insulin bolus. They included 59 patients in the bolus group, and 108 in the non-bolus group. The study primarily tracked whether the administration of insulin had to be interrupted, or if patients experienced hypoglycemia or hypokalemia within eight hours of starting insulin. Comparing baseline characteristics, the groups showed no significant differences. Most patients exhibited mild DKA. Results revealed that adverse effects—particularly hypokalemia—occurred significantly more often in the bolus group (45.8% versus 25%, P = .003). Additionally, while time to anion gap closure was shorter in the bolus group, this did not reach statistical significance (6:39 versus 9:00, P = .063). Similarly, non-significant differences emerged in time to discontinuation of insulin infusion and time to ICU and hospital discharge. […]

A retrospective cohort study was conducted to investigate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) for individuals without preexisting cardiovascular disease. The study included US veterans aged 18 or older who were receiving care from the Veterans Health Administration. The cohort consisted of patients who added either GLP1RA, SGLT2i, or dipeptidyl peptidase-4 inhibitors (DPP4i) to their existing diabetes treatments. The outcomes measured were MACE and heart failure hospitalization. The results showed that the addition of GLP1RA was associated with a lower incidence of MACE and heart failure compared to DPP4i. However, the addition of SGLT2i did not show a significant association with primary prevention of MACE.